Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc.

 
DOCKET NO.
OP. BELOW
SUBJECT
Patent

Question(s) Presented

“Whether a court must consider objective indicia of nonobviousness together with the other factors bearing on an obviousness challenge before making any obviousness determination.”

Posts About this Case

Date
Proceedings and Orders
March 24, 2021
DISTRIBUTED for Conference of 4/16/2021.
March 30, 2021
Response Requested. (Due April 29, 2021)
April 7, 2021
Motion to extend the time to file a response is granted in part and the time is extended to and including May 18, 2021.